Feng Wang, Ying Jin, Min Wang, Hui-Yan Luo, Wei-Jia Fang, Ying-Nan Wang, Yan-Xing Chen, Run-Jie Huang, Wen-Long Guan, Ji-Bin Li, Yu-Hong Li, Feng-Hua Wang, Xiao-Hua Hu, Yan-Qiao Zhang, Miao-Zhen Qiu, Lu-Lu Liu, Zi-Xian Wang, Chao Ren, De-Shen Wang, Dong-Sheng Zhang, Zhi-Qiang Wang, Wen-Ting Liao, Lin Tian, Qi Zhao, Rui-Hua Xu
Epigenetic modifications of chromatin, including histone acetylation, and tumor angiogenesis play pivotal roles in creating an immunosuppressive tumor microenvironment. In the randomized phase 2 CAPability-01 trial, we investigated the potential efficacy of combining the programmed cell death protein-1 (PD-1) monoclonal antibody sintilimab with the histone deacetylase inhibitor (HDACi) chidamide with or without the anti-vascular endothelial growth factor (VEGF) monoclonal antibody bevacizumab in patients with unresectable chemotherapy-refractory locally advanced or metastatic microsatellite stable/proficient mismatch repair (MSS/pMMR) colorectal cancer...
March 4, 2024: Nature Medicine